Brigatinib

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Brigatinib (AP-26113, AP26113) is a potent, selective, second generation ALK inhibitor with IC50 of 0.62 nM.

Brigatinib (AP-26113, AP26113) is a potent, selective, second generation ALK inhibitor with IC50 of 0.62 nM, exhibits about fivefold greater potency in vitro compared with crizotinib; shows high activity against both sensitive and resistant H3122 cells, decreasing cell growth, suppressing ALK phosphorylation, and inducing apoptosis; AP26113 is also active in Ba/F3 cells expressing either native or mutant EML4-ALK with IC50 of 10 and 24 nM, respectively; demonstrates promising activity in crizotinib resistant.Lung Cancer Approved

AP-26113;AP26113

Angiogenesis

ALK

ALK;EGFR(C797S/del19);FLT3;IGF-1R;ROS1

Cancer

Lung Cancer

1197953-54-0

584.09

C29H39ClN7O2P

>98% (HPLC)

10 mM in Ethanol

CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC

2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-

(-20℃)

With Ice Pack

≥ 2 years